7Baggers
The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.

ZyVersa Therapeutics, Inc.
(NASDAQ:ZVSA) 

ZVSA stock logo

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and...

Founded: 2014
Full Time Employees: 6
Sector: Healthcare
Industry: Biotechnology
Healthcare
Share this website to your friends
ZyVersa Therapeutics . Days Payable Outstanding ttm (DPO)
202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 044.6189.22133.83178.44223.05267.66312.27Thousand
ZyVersa Therapeutics . Op Cashflow Per Share ttm
202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -2.15-1.84-1.54-1.23-0.92-0.61-0.310
ZyVersa Therapeutics . Free Cashflow Per Share ttm
202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -2.15-1.84-1.54-1.23-0.92-0.61-0.310
ZyVersa Therapeutics . Cash Per Share ttm
202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 00.110.220.330.440.550.660.77
ZyVersa Therapeutics . (GAAP) P/E ratio ttm
202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -14.23-12.2-10.17-8.13-6.1-4.07-2.030
ZyVersa Therapeutics . P/B ratio ttm
202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -6.95-5.72-4.5-3.27-2.04-0.820.411.64
No extra charts and metrics for this ticker.